Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

blonca9
Feb 26, 2024
1 min read

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies and how Lyell is manufacturing its products to improve potency. Plus, a discussion on ROR1 as a solid tumor target for CAR-T.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight